Corbus Pharmaceuticals Holdings, Inc. announced the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4. The Phase 1 portion of the open label study design (NCT06265727), being conducted in the U.S. and Europe, will evaluate the safety, efficacy and pharmacokinetics (PK) of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression. The Phase 1 trial initiates with dose escalation followed by dose optimization and concludes with dose expansion to determine the recommended Phase 2 dose.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.99 USD | -1.71% | +10.88% | +611.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+611.75% | 452M | |
+3.91% | 109B | |
+10.87% | 105B | |
-0.03% | 22.25B | |
-13.14% | 22.09B | |
-7.77% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CRBP Stock
- News Corbus Pharmaceuticals Holdings, Inc.
- Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC